Nature, Published online: 03 November 2026; doi:10.1038/d41586-026-03504-2
Physicians were excited about several therapies that slash levels of lipoprotein(a) — an important cardiovascular risk factor. One major trial failed to show a benefit, and now scientists are scrambling to work out what that means.General
This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope?
Nature News0 views
Source:https://www.nature.com/articles/d41586-026-03504-2
PreviousWill AI grant reviews make science more conservative?NextDaily briefing: ‘A triumph of scientific self-correction’
Related posts
Showcase: SKILLVERSE – A platform to learn skills, build projects, and prove your potential
0dev.to WebDev
Federal Advisory Committees – Terminations and Archive Status
0Hacker News New
Museum of Civil Liberties
0Hacker News New
Americans bet $1.9B on midterms; markets favor Democrats in House and Senate
0Hacker News New
What Millions of Data Points Reveal About US Inflation
0Hacker News New
Continuity Infrastructure [video]
0Hacker News New